Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

OBJECTIVES: More and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunotherapy is still a controversy for NSCLC patients...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Chen, Ya, Yang, Zhengyu, Wang, Yanan, Hu, Minjuan, Zhang, Bo, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Han, Baohui
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2021
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085497/
https://ncbi.nlm.nih.gov/pubmed/33937084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.671228
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires